摘要
目的探讨普拉克索联合左旋多巴治疗帕金森病(PD)的有效性和安全性。方法选取我院收治的48例PD患者,随机均分为对照组和观察组,对照组使用左旋多巴治疗,观察组使用普拉克索联合左旋多巴治疗。在第4、8和12周末使用统一帕金森病评定量表(UPDRS)和汉密顿抑郁量表(HAMD)评价,在第21周末使用TESS量表评价2组患者不良反应。结果 2组患者第4、8和12周末UPDRS和HAMD评分均较基线评分明显改善(P<0.05);治疗12周后,观察组患者UPDRSⅠ、Ⅱ、Ⅲ、Ⅳ评分和HAMD评分均显著优于对照组,2组比较差异有统计学意义(P<0.05);2组患者TESS评分比较无显著差异(P>0.05)。结论普拉克索联合左旋多巴治疗PD患者效果确切,能有效改善UPDRS和HAMD评分,减少并发症的发生。
Objective To investigate clinical efficacy and safety of pramipexole combined with levodopa on patients with Parkinson＆#39;s disease.Methods Forty-eight cases with Parkinson＆#39;s disease in our hospital were randomly divided into control group and observation group. Control group were received levodopa.Observation group were received pramipexole combined with levodopa. The scores of the Unified Parkinson＆#39;s Disease Rating Scale（UPDRS）and Hamilton Depression Scale（HAMD）of two groups after treatment for 4 ,8 and 12 weeks were compared. The adverse reaction rate of two groups after 12 weeks were compared based on TESS scales.Results The HAMD and UPDRS scores of two groups after 4 ,8 and 12 weeks were signifi-cantly improved than baseline score（P〈0.05）.The UPDRSⅠ ,Ⅱ ,Ⅲ ,Ⅳ score and HAMD score of observation group were significantly better than those of control group. The TESS scores of two groups had no significant difference （P〉 0.05）.Conclusion Pramipexole combined with levodopa for Parkinson＆#39;s disease patients has exact effect. It can significantly improve UPDRS and HAMD score and reduce complications.
出处
《中国实用神经疾病杂志》
2014年第9期37-39,共3页
Chinese Journal of Practical Nervous Diseases
关键词
普拉克索
左旋多巴
帕金森病
Pramipexole
Levodopa
Parkinson＆#39
s disease
